(Q37813046)

23 August 2017

1 reference

title

Osteoporosis in men: what has changed? (English)

1 reference

23 August 2017

0 references

Robert A Adler

1

1 reference

23 August 2017

publication date

1 March 2011

1 reference

Current osteoporosis reports

23 August 2017

published in

1 reference

23 August 2017

volume

9

1 reference

23 August 2017

issue

1

1 reference

23 August 2017

page(s)

31-35

1 reference

Risk-adjusted mortality rates of elderly veterans with hip fractures.

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0039-7

Involutional osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0039-7

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0039-7

Risk factors for low BMD in healthy men age 50 years or older: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0039-7

Male risk factors for hip fracture-a 30-year follow-up study in 7,495 men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0039-7

BMD and risk of hip and nonvertebral fractures in older men: a prospective study and comparison with older women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0039-7

Association of Testosterone and Estradiol Deficiency with Osteoporosis and Rapid Bone Loss in Older Men

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0039-7

Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0039-7

Adverse events associated with testosterone administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0039-7

Loss of hip BMD in older men: the osteoporotic fractures in men (MrOS) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0039-7

Rate and circumstances of clinical vertebral fractures in older men

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0039-7

Update in male osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0039-7

Survival following primary androgen deprivation therapy among men with localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0039-7

Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0039-7

Bone mineral density and prevalent osteoarthritis of the hip in older men for the Osteoporotic Fractures in Men (MrOS) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0039-7

Approach to the prostate cancer patient with bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0039-7

Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0039-7

Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0039-7

Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0039-7

Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0039-7

The effects of a FRAX revision for the USA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0039-7

Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0039-7

Zoledronic acid and clinical fractures and mortality after hip fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0039-7

Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0039-7

Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0039-7

The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0039-7

Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0039-7

Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0039-7

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0039-7

Alendronate for the Treatment of Osteoporosis in Men

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0039-7

Bone mineral density and prevalent vertebral fractures in men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0039-7

Identification of late-onset hypogonadism in middle-aged and elderly men.

21 January 2018

1 reference

12 December 2020

Risk factors for incident vertebral fractures in men and women: the Rotterdam Study

1 reference

12 December 2020

Screening for osteoporosis: an update for the U.S. Preventive Services Task Force

1 reference

12 December 2020

Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer

1 reference

12 December 2020

Zoledronic acid treatment of osteoporosis: effects in men.

1 reference

12 December 2020

Estimates of the proportion of older white men who would be recommended for pharmacologic treatment by the new US National Osteoporosis Foundation guidelines

1 reference

12 December 2020

Risk of fracture after androgen deprivation for prostate cancer

1 reference

12 December 2020

Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study

1 reference

12 December 2020

10.1007/S11914-010-0039-7

Identifiers

DOI

1 reference

23 August 2017

1 reference